JAZZ PHARMACEUT. DL-,0001
JAZZ PHARMACEUT. DL-,0001/ IE00B4Q5ZN47 /
J7Z
17/05/2024 08:08:13
|
Chg.
+0.90
|
Volume |
Bid20:59:37 |
Demandez à20:59:37 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
101.10EUR
|
+0.90%
|
0 Chiffrre d'affaires: 0.00 |
99.56Bid taille: 200 |
100.00Ask la taille: 200 |
6.32 Mrd.EUR |
- |
- |
Description de l'entreprise
At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again. We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.
Conseil d'administration & Conseil de surveillance
PDG |
Bruce C. Cozadd |
Conseil d'administration |
Pater Gray, Jeninfer Cook, Patrcik G. Enright, Heather Ann McSharry, Seamus Mulligan |
Conseil de surveillance |
- |